NASDAQ:KLRS

Kalaris Therapeutics (KLRS) Stock Price, News & Analysis

Kalaris Therapeutics logo
$1.28 -0.07 (-5.19%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.29 +0.01 (+0.78%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Kalaris Therapeutics Stock (NASDAQ:KLRS)

Advanced

Key Stats

Today's Range
$1.25
▼
$1.37
50-Day Range
$1.28
▼
$3.30
52-Week Range
$1.25
▼
$11.88
Volume
37,986 shs
Average Volume
84,329 shs
Market Capitalization
$30.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.75
Consensus Rating
Moderate Buy

Company Overview

Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. Its work centers on advancing investigational therapies intended to address conditions affecting vision.

The company’s product candidates are in development and are not approved for commercial use. Kalaris’s activities include research and development and the clinical evaluation of potential therapies.

Publicly available information about the company’s leadership and geographic operations is limited.

AI Generated. May Contain Errors.

Kalaris Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

KLRS MarketRank™: 
1.870533837745 of 5 stars

Kalaris Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 647th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kalaris Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Kalaris Therapeutics has a consensus price target of $18.75, representing about 1,364.8% upside from its current price of $1.28.

  • Amount of Analyst Coverage

    Kalaris Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Kalaris Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Kalaris Therapeutics are expected to decrease in the coming year, from ($1.92) to ($1.97) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kalaris Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kalaris Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Kalaris Therapeutics has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.83% of the float of Kalaris Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Kalaris Therapeutics has a short interest ratio ("days to cover") of 5.43.
  • Change versus previous month

    Short interest in Kalaris Therapeutics has recently increased by 19.66%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Kalaris Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Kalaris Therapeutics does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Kalaris Therapeutics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    2 people have added Kalaris Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Kalaris Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    68.10% of the stock of Kalaris Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    66.05% of the stock of Kalaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Kalaris Therapeutics' insider trading history.
Receive KLRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kalaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

KLRS Stock News Headlines

URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
Kalaris Therapeutics Inc
Kalaris Therapeutics Reports Q3 Net Loss
Kalaris Therapeutics Inc (KLRS)
See More Headlines

KLRS Stock Analysis - Frequently Asked Questions

Kalaris Therapeutics' stock was trading at $8.44 at the beginning of the year. Since then, KLRS shares have decreased by 84.8% and is now trading at $1.28.

Kalaris Therapeutics Inc. (NASDAQ:KLRS) released its earnings results on Tuesday, November, 10th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.06.

Top institutional investors of Kalaris Therapeutics include Goldman Sachs Group Inc. (0.17%), Empowered Funds LLC (0.09%) and Independent Advisor Alliance (0.05%).
View institutional ownership trends
.

Shares of KLRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/10/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:KLRS
CIK
1754068
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$25.00
Low Price Target
$14.00
Potential Upside/Downside
+1,364.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.84)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.44 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-68.76%
Return on Assets
-41.32%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.00
Quick Ratio
10.00

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.99 per share
Price / Book
0.64

Miscellaneous

Outstanding Shares
23,805,000
Free Float
7,594,000
Market Cap
$30.47 million
Optionable
N/A
Beta
0.47
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:KLRS) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners